Coherus Oncology (CHRS) Resumen de Acciones
Coherus Oncology, Inc. es una empresa biofarmacéutica que investiga, desarrolla y comercializa inmunoterapias para tratar el cáncer en Estados Unidos. Saber más
| Puntuación del snowflake | |
|---|---|
| Valoración | 3/6 |
| Crecimiento futuro | 2/6 |
| Rendimiento pasado | 0/6 |
| Salud financiera | 5/6 |
| Dividendos | 0/6 |
Recompensas
Análisis de riesgos
CHRS Community Fair Values
Create NarrativeSee what 21 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Top Community Narratives
Coherus Oncology
91.4% infravalorado descuento intrínseco
Coherus BioSciences will see 16% revenue growth driving future value
View narrativeNE
Updated 12 Mar 2025
Competidores de Coherus Oncology, Inc.
Historial de precios y rendimiento
| Precios históricos de las acciones | |
|---|---|
| Precio actual de la acción | US$1.33 |
| Máximo en las últimas 52 semanas | US$2.62 |
| Mínimo de 52 semanas | US$1.09 |
| Beta | 0.94 |
| Cambio en 1 mes | 10.83% |
| Variación en 3 meses | -3.62% |
| Cambio de 1 año | 4.72% |
| Variación en 3 años | -70.64% |
| Variación en 5 años | -92.35% |
| Variación desde la OPV | -89.45% |
Noticias y actualizaciones recientes
Seeking Alpha • Aug 19
Coherus: 'Hold' On Several Tagmokitug 2026 Catalysts And Casdozokitug HCC Drug Development
Summary Coherus Oncology retains a "Hold" rating as multiple pivotal data readouts approach for its lead oncology candidates in 2H 2026. The company's tagmokitug and casdozokitug programs offer multiple shots on goal, targeting large solid tumor markets, but further proof-of-concept is key to success. Initial phase 2 CADILYZE data for casdozokitug in 1st-line unresectable HCC is expected in Q4 2026, representing a major inflection point. The company faces near-term cash constraints, with funding sufficient for only 12 months and potential dilution risk if additional capital is required. Read the full article on Seeking Alpha
Actualización de narrativa • Aug 07
CHRS: Anti Tumor Readouts And New Trial Collaboration Will Drive Future Upside
Analysts have trimmed their price target on Coherus Oncology to $10 from $12, citing updated assumptions around discount rates, revenue growth, profit margins, and future P/E levels. Analyst Commentary Bullish analysts covering Coherus Oncology continue to highlight reasons they see upside potential in the stock, even as formal price targets are reassessed.
Actualización de narrativa • Jul 02
CHRS: Anti Tumor Collaboration Will Shape Bullish Outlook
Coherus Oncology's analyst price target has shifted from $6.75 to $7.80, with analysts pointing to updated assumptions around revenue growth, profit margin expectations, and a lower future P/E multiple following recent research highlighting the company's anti tumor potential. What’s in the News for Coherus Oncology Coherus Oncology and Zumutor Biologics entered a clinical collaboration and supply agreement to run a Phase 1 trial of ZM008, an NK checkpoint anti LLT1 antibody, in combination with LOQTORZI (toripalimab tpzi) across several solid tumor types in the United States.Recent updates
Seeking Alpha • Aug 19
Coherus: 'Hold' On Several Tagmokitug 2026 Catalysts And Casdozokitug HCC Drug Development
Summary Coherus Oncology retains a "Hold" rating as multiple pivotal data readouts approach for its lead oncology candidates in 2H 2026. The company's tagmokitug and casdozokitug programs offer multiple shots on goal, targeting large solid tumor markets, but further proof-of-concept is key to success. Initial phase 2 CADILYZE data for casdozokitug in 1st-line unresectable HCC is expected in Q4 2026, representing a major inflection point. The company faces near-term cash constraints, with funding sufficient for only 12 months and potential dilution risk if additional capital is required. Read the full article on Seeking AlphaActualización de narrativa • Aug 07
CHRS: Anti Tumor Readouts And New Trial Collaboration Will Drive Future Upside
Analysts have trimmed their price target on Coherus Oncology to $10 from $12, citing updated assumptions around discount rates, revenue growth, profit margins, and future P/E levels. Analyst Commentary Bullish analysts covering Coherus Oncology continue to highlight reasons they see upside potential in the stock, even as formal price targets are reassessed.Actualización de narrativa • Jul 02
CHRS: Anti Tumor Collaboration Will Shape Bullish Outlook
Coherus Oncology's analyst price target has shifted from $6.75 to $7.80, with analysts pointing to updated assumptions around revenue growth, profit margin expectations, and a lower future P/E multiple following recent research highlighting the company's anti tumor potential. What’s in the News for Coherus Oncology Coherus Oncology and Zumutor Biologics entered a clinical collaboration and supply agreement to run a Phase 1 trial of ZM008, an NK checkpoint anti LLT1 antibody, in combination with LOQTORZI (toripalimab tpzi) across several solid tumor types in the United States.
Actualización de narrativa • Jun 18
CHRS: Anti Tumor Potential And Accounting Shift Will Drive Future Upside
Analysts now frame Coherus Oncology around a revised price target of $4.00, reflecting updated assumptions on discount rate, revenue growth, profit margin and future P/E, with Guggenheim's recent coverage citing the company's anti tumor potential as a key part of the rationale. What’s in the News for Coherus Oncology Coherus Oncology changed its independent registered public accounting firm on June 12, 2026, as the Audit Committee dismissed Ernst & Young LLP, effective the same day.Actualización de narrativa • Jun 03
CHRS: Anti Tumor Potential And Upcoming Readouts Will Shape Future Upside
Analysts have lifted their price target on Coherus Oncology to $4.00, citing stronger projected revenue growth, higher expected profit margins, and a lower future P/E multiple following recent Street research pointing to the company’s anti tumor potential. What's in the News No recent news items, periodical coverage, or key developments were provided for Coherus Oncology as of Wednesday, 3 Jun 2026.Actualización de narrativa • May 16
CHRS: Anti Tumor Readouts Will Shape Future Revenue Visibility And Profitability
Analysts have raised their fair value estimate for Coherus Oncology stock from $10.00 to $12.00, citing Guggenheim's recent initiation focused on the company's anti tumor potential as a key driver behind the updated price target and more optimistic assumptions around revenue growth, profit margins, and future P/E. Analyst Commentary Analysts pointing to the anti tumor opportunity see the recent fair value move to US$12.00 as a sign that expectations for the stock are improving, particularly in how the market might value future oncology revenue and profitability.Actualización de narrativa • Apr 29
CHRS: Lock Ups And Recent Equity Raise Will Shape Bullish Outlook
Analysts have adjusted their price target on Coherus Oncology to $6.75, reflecting updated views on discount rates, profit margin assumptions, and future P/E expectations, while keeping the fair value estimate unchanged at $6.75. What's in the News Lock up agreements on certain stock options of Coherus Oncology, Inc.Actualización de narrativa • Apr 15
CHRS: Upcoming Readouts And New Outperform Coverage Will Shape Oncology Upside
Analysts have lifted their price target on Coherus Oncology to $4.00, citing updated expectations for revenue growth, profit margins, and a slightly higher future P/E multiple informed by recent bullish research and new Outperform coverage ahead of key readouts. Analyst Commentary Recent research points to growing interest in Coherus Oncology as analysts respond to fresh coverage ahead of key clinical readouts.Actualización de narrativa • Apr 01
CHRS: Upcoming Readouts And Equity Raises Will Shape Oncology Outlook
Analysts have lifted their price target on Coherus Oncology to $6.75, highlighting higher assumed revenue growth of 64.35%, a stronger profit margin of 14.76% and a modestly lower future P/E of 55.41x, following fresh bullish coverage ahead of key readouts. Analyst Commentary Bullish Takeaways Bullish analysts see the new coverage and price target as a vote of confidence in Coherus Oncology's ability to convert its pipeline into revenue growth, reflected in the 64.35% revenue growth assumption built into current models.Actualización de narrativa • Mar 18
CHRS: Upcoming Readouts And Biomarker Data Will Support Stronger Oncology Outlook
Analysts have raised their price target on Coherus Oncology to $4.00, presenting the unchanged fair value in conjunction with a lower discount rate and significantly higher modeled revenue growth, while citing recent bullish initiation and Outperform ratings ahead of key readouts. Analyst Commentary Recent research coverage frames Coherus Oncology as a higher risk, higher reward idea, with enthusiasm around upcoming readouts balanced by concerns about execution and the durability of modeled revenue growth.Actualización de narrativa • Mar 03
CHRS: Upcoming Readouts And New Collaboration Will Shape Oncology Pipeline Outlook
Analysts have kept their average $6.75 price target on Coherus Oncology steady, as recent bullish coverage and Outperform initiations are balanced by updated assumptions that include a lower projected profit margin and a higher future P/E multiple. Analyst Commentary Bullish Takeaways Bullish analysts highlight that fresh Outperform initiations signal confidence that the current share price already reflects more cautious margin and P/E assumptions.Actualización de narrativa • Feb 17
CHRS: Upcoming Clinical Readouts Will Drive Reassessment Of Oncology Pipeline Potential
Analysts have raised their price target on Coherus Oncology from about $5.67 to $6.75, citing updated assumptions on revenue trends, margins, and future P/E following recent bullish coverage and the initiation of coverage on the name ahead of key clinical readouts. Analyst Commentary Bullish Takeaways Bullish analysts point to upcoming clinical readouts as a key potential catalyst that could help support the higher price target and justify updated P/E assumptions.Actualización de narrativa • Feb 03
CHRS: Upcoming Readouts Will Shape Revenue Visibility And Profitability Expectations
Analysts have raised their fair value estimate for Coherus Oncology from US$7.00 to US$10.00, citing a more constructive view on revenue trends, profitability and future P/E assumptions following recent bullish coverage ahead of key readouts. Analyst Commentary Recent research coverage has leaned positive, with bullish analysts pointing to a more constructive setup around upcoming clinical readouts and the valuation reset implied by the higher fair value estimate.Actualización de narrativa • Jan 20
CHRS: Future Biomarker And Index Inclusion Catalysts Will Support Stronger Oncology Outlook
Analysts have made a slight adjustment to their price target on Coherus Oncology to reflect updated assumptions around discount rate, revenue growth, and margins, while maintaining their fair value estimate at approximately $4.00 per share. What's in the News Coherus Oncology published preclinical and clinical biomarker research in Molecular Cancer Therapeutics on its anti CCR8 monoclonal antibody, now named tagmokitug, highlighting high selectivity, picomolar binding affinity and effector mediated killing of CCR8+ cells, with no off target binding reported (Molecular Cancer Therapeutics, December 2025).Artículo de análisis • Jan 10
There's No Escaping Coherus Oncology, Inc.'s (NASDAQ:CHRS) Muted Revenues Despite A 27% Share Price Rise
Coherus Oncology, Inc. ( NASDAQ:CHRS ) shareholders would be excited to see that the share price has had a great month...Actualización de narrativa • Jan 06
CHRS: Future Immune Activation And Biomarker Data Will Support Stronger Oncology Outlook
Analysts have maintained their price target for Coherus Oncology at US$4.00, citing updates to revenue decline assumptions, a slightly lower discount rate, a small improvement in projected profit margins, and a reduced future P/E multiple as the key drivers of the refreshed view. What's in the News Publication of preclinical and clinical biomarker research in Molecular Cancer Therapeutics on tagmokitug, an investigational anti-CCR8 monoclonal antibody with high selectivity and picomolar binding affinity targeting CCR8+ T regulatory cells in solid tumors (Molecular Cancer Therapeutics).Actualización de narrativa • Dec 13
CHRS: Future Immune Activation Data Will Support Stronger Oncology Outlook
Analysts have raised their price target for Coherus Oncology to approximately 4.00 dollars from about 1.10 dollars, citing a less severe expected revenue decline, a slight improvement in projected profit margins, and a marginally higher future earnings multiple, despite a modestly increased discount rate. What's in the News New multiomic tumor and blood biomarker data from the Phase 1b dose expansion arm of CHS-114 in recurrent or metastatic head and neck squamous cell carcinoma show significantly enhanced and sustained immune activation when combined with toripalimab (Key Developments).Artículo de análisis • Nov 14
Revenues Working Against Coherus Oncology, Inc.'s (NASDAQ:CHRS) Share Price Following 26% Dive
The Coherus Oncology, Inc. ( NASDAQ:CHRS ) share price has softened a substantial 26% over the previous 30 days...Actualización de narrativa • Sep 11
Upcoming Clinical Data Will Reshape Immuno-Oncology Amid Uncertainties
Despite a decline in net profit margin, Coherus Oncology's significantly higher future P/E ratio reflects increased investor optimism, resulting in a raised consensus price target from $4.70 to $5.67. What's in the News Coherus Oncology received a deficiency notice from Nasdaq after its common stock closed below $1.00 per share for 30 consecutive business days, putting it at risk of delisting.Artículo de análisis • Aug 10
Industry Analysts Just Upgraded Their Coherus Oncology, Inc. (NASDAQ:CHRS) Revenue Forecasts By 21%
NasdaqGM:CHRS 1 Year Share Price vs Fair Value Explore Coherus Oncology's Fair Values from the Community and select...Artículo de análisis • Jul 24
Coherus Oncology, Inc.'s (NASDAQ:CHRS) Price Is Right But Growth Is Lacking After Shares Rocket 35%
Those holding Coherus Oncology, Inc. ( NASDAQ:CHRS ) shares would be relieved that the share price has rebounded 35% in...Artículo de análisis • May 18
Coherus BioSciences, Inc.'s (NASDAQ:CHRS) 32% Dip In Price Shows Sentiment Is Matching Revenues
The Coherus BioSciences, Inc. ( NASDAQ:CHRS ) share price has fared very poorly over the last month, falling by a...Artículo de análisis • May 15
Some Coherus BioSciences, Inc. (NASDAQ:CHRS) Analysts Just Made A Major Cut To Next Year's Estimates
Market forces rained on the parade of Coherus BioSciences, Inc. ( NASDAQ:CHRS ) shareholders today, when the analysts...Seeking Alpha • Apr 17
Coherus BioSciences: Cleaning The Balance Sheet And Developing New Drugs
Summary Coherus BioSciences is now heavily focused on developing its pipeline, particularly casdozokitug and CHS-114, after shedding its marketed biosimilar drugs. Casdozokitug shows promise in metastatic hepatocellular carcinoma with a 17.2% complete response rate in phase 1 and is now in a phase 2 study. CHRS is still marketing Loqtorzi for nasopharyngeal carcinoma, with Q4'24 revenues of $7.5M representing 29% growth over the prior quarter. Read the full article on Seeking Alpha
Nueva narrativa • Apr 03
UDENYCA Divestiture And LOQTORZI Progress Will Forge Opportunity Amid Risks
UDENYCA divestiture and headcount reduction will strengthen the balance sheet and improve margins through reduced expenses.Artículo de análisis • Mar 28
Lacklustre Performance Is Driving Coherus BioSciences, Inc.'s (NASDAQ:CHRS) 27% Price Drop
To the annoyance of some shareholders, Coherus BioSciences, Inc. ( NASDAQ:CHRS ) shares are down a considerable 27% in...Artículo de análisis • Mar 24
Shareholders Shouldn’t Be Too Comfortable With Coherus BioSciences' (NASDAQ:CHRS) Strong Earnings
Strong earnings weren't enough to please Coherus BioSciences, Inc.'s ( NASDAQ:CHRS ) shareholders over the last week...Artículo de análisis • Dec 21
There's No Escaping Coherus BioSciences, Inc.'s (NASDAQ:CHRS) Muted Revenues Despite A 38% Share Price Rise
Despite an already strong run, Coherus BioSciences, Inc. ( NASDAQ:CHRS ) shares have been powering on, with a gain of...Seeking Alpha • Dec 16
Coherus BioSciences: Shedding Pegfilgrastim To Fuel Ongoing Development
Summary Coherus BioSciences focuses on immunotherapy, expanding their PD-1 antibody market, and developing novel treatments for solid tumors, despite maintaining a penny stock valuation. Financially, CHRS holds $97.7 million in cash, $36.6 million in term loans, and $227.9 million in convertible notes, with $70.8 million in net revenues. CHRS is divesting their Udenyca franchise for $483.4 million, with potential milestone payments, following previous sales of Cimerli and Yusimry franchises. CHRS's financial and strategic moves indicate a cautious yet potentially rewarding horizon for investors. Read the full article on Seeking AlphaArtículo de análisis • Nov 06
Investors Don't See Light At End Of Coherus BioSciences, Inc.'s (NASDAQ:CHRS) Tunnel And Push Stock Down 30%
To the annoyance of some shareholders, Coherus BioSciences, Inc. ( NASDAQ:CHRS ) shares are down a considerable 30% in...Artículo de análisis • Sep 22
Revenues Working Against Coherus BioSciences, Inc.'s (NASDAQ:CHRS) Share Price Following 27% Dive
Unfortunately for some shareholders, the Coherus BioSciences, Inc. ( NASDAQ:CHRS ) share price has dived 27% in the...Seeking Alpha • Aug 13
Evaluating Coherus BioSciences: Udenyca's Success And Loqtorzi's Prospects
Summary Coherus BioSciences, Inc. focuses on biosimilars and immuno-oncology treatments, with LOQTORZI and UDENYCA as key products. Coherus BioSciences' biosimilar IP shows potential for profitability, with strategic divestitures impacting its financial position post Q3 2024. UDENYCA drives most of CHRS's revenues, positioning it as its crown jewel with a 29% market share and strong payer coverage. The success of UDENYCA and the potential growth from LOQTORZI are critical to avoiding dilution risks and ensuring long-term financial stability. Despite some cash runway concerns, CHRS trades at a low valuation, so it leans towards a speculative “buy” for investors who understand the embedded biotech risks. Read the full article on Seeking AlphaArtículo de análisis • Aug 07
Why Investors Shouldn't Be Surprised By Coherus BioSciences, Inc.'s (NASDAQ:CHRS) Low P/S
You may think that with a price-to-sales (or "P/S") ratio of 0.5x Coherus BioSciences, Inc. ( NASDAQ:CHRS ) is...Seeking Alpha • May 31
Coherus BioSciences: CHS-114 Comes Into View At ASCO, Drug Launches Underway
Summary Coherus BioSciences, Inc. is relying on revenues from existing drugs and its developmental pipeline after selling off a major source of revenue in Cimerli. CHS-114, an anti-CCR8 antibody being developed by CHRS, is set to produce data at the ASCO 2024 Annual Meeting. Coherus BioSciences refers to Yusimry (a biosimilar Humira) as a non-core product, and could look to sell the drug, although revenues are growing. Read the full article on Seeking AlphaArtículo de análisis • May 23
Shareholders May Be More Conservative With Coherus BioSciences, Inc.'s (NASDAQ:CHRS) CEO Compensation For Now
Key Insights Coherus BioSciences to hold its Annual General Meeting on 29th of May Total pay for CEO Denny Lanfear...Seeking Alpha • Mar 21
Coherus Biosciences: Dumping One Drug But Showing Promise With Another
Summary CHRS has sold Cimerli, a Lucentis biosimilar, to SDZNY. CHRS anti-IL-27 antibody, casdozokitug, shows promising results as part of a triple therapy in hepatocellular carcinoma, with an overall response rate of 38%. Numbers on market share point to a strong Q1'24 for Udenyca, which could increase the market's confidence that CHRS can offset lost revenues from the Cimerli sale. CHRS has data in H1'24 from a phase 1 trial of its anti-CCR8 antibody, CHS-114, in solid tumors, adding a catalyst to the calendar. Read the full article on Seeking AlphaArtículo de análisis • Feb 03
Revenues Working Against Coherus BioSciences, Inc.'s (NASDAQ:CHRS) Share Price Following 29% Dive
Unfortunately for some shareholders, the Coherus BioSciences, Inc. ( NASDAQ:CHRS ) share price has dived 29% in the...Seeking Alpha • Jan 17
Coherus BioSciences: FDA Approvals Spice Up The Pipeline
Summary CHRS has a pipeline of biosimilars including Yusimry, Cimerli, and Udenyca. A new form of Udenyca, Udenyca Onbody, was approved in December 2023. CHRS also has a new drug Loqtorzi (toripalimab) which was approved in the US for the treatment of nasopharyngeal carcinoma in October 2023. Approval of Loqtorzi is a key step towards creating a revenue source with a greater moat versus biosimilars. Read the full article on Seeking AlphaArtículo de análisis • Dec 20
Investors Aren't Buying Coherus BioSciences, Inc.'s (NASDAQ:CHRS) Revenues
You may think that with a price-to-sales (or "P/S") ratio of 1.1x Coherus BioSciences, Inc. ( NASDAQ:CHRS ) is...Rentabilidad de los accionistas
| CHRS | US Biotechs | Mercado US | |
|---|---|---|---|
| 7D | -6.3% | -5.2% | -0.9% |
| 1Y | 4.7% | 38.0% | 13.9% |
Rentabilidad vs. Industria: Los resultados de CHRS fueron inferiores a los de la industria US Biotechs, que obtuvo un rendimiento del 38% el año pasado.
Rentabilidad vs. Mercado: CHRS obtuvo unos resultados inferiores a los del mercado US, que fueron del 13.9% el año pasado.
Volatilidad de los precios
| CHRS volatility | |
|---|---|
| CHRS Average Weekly Movement | 9.5% |
| Biotechs Industry Average Movement | 9.5% |
| Market Average Movement | 6.9% |
| 10% most volatile stocks in US Market | 15.3% |
| 10% least volatile stocks in US Market | 2.9% |
Precio estable de las acciones: CHRS no ha tenido una volatilidad de precios significativa en los últimos 3 meses en comparación con el mercado US.
Volatilidad a lo largo del tiempo: La volatilidad semanal de CHRS (10%) se ha mantenido estable durante el año pasado.
Acerca de la empresa
| Fundada | Empleados | CEO | Página web |
|---|---|---|---|
| 2010 | 144 | Denny Lanfear | www.coherus.com |
Coherus Oncology, Inc., una empresa biofarmacéutica, investiga, desarrolla y comercializa inmunoterapias para el tratamiento del cáncer en Estados Unidos. La empresa desarrolla UDENYCA, un biosimilar de Neulasta, un factor estimulante de colonias de granulocitos de acción prolongada; LOQTORZI, un novedoso inhibidor de la próxima generación del receptor de muerte programada 1; y Casdozokitug, un anticuerpo monoclonal recombinante de isotipo de inmunoglobulina humana (IgG1) en fase de investigación dirigido contra la interleucina IL-27. También desarrolla CHS-114, un anticuerpo monoclonal humano afucosilado de isotipo IgG1 en fase de investigación, dirigido contra un receptor de quimiocinas altamente expresado en las células Treg del microambiente tumoral (TME) de pacientes con carcinoma escamoso de cabeza y cuello.
Resumen de fundamentos de Coherus Oncology, Inc.
| Estadísticas fundamentales de CHRS | |
|---|---|
| Capitalización bursátil | US$205.49m |
| Beneficios(TTM) | -US$161.15m |
| Ingresos (TTM) | US$50.94m |
4.0x
Ratio precio-ventas (PS)-1.3x
Ratio precio-beneficio (PE)¿Está CHRS sobrevalorada?
Ver valor justo y análisis de valoraciónBeneficios e Ingresos
| Cuenta de resultados (TTM) de CHRS | |
|---|---|
| Ingresos | US$50.94m |
| Coste de los ingresos | US$15.81m |
| Beneficio bruto | US$35.12m |
| Otros gastos | US$196.27m |
| Beneficios | -US$161.15m |
Últimos beneficios comunicados
Jun 30, 2026
Próxima fecha de beneficios
n/a
| Beneficios por acción (BPA) | -1.04 |
| Margen bruto | 68.96% |
| Margen de beneficio neto | -316.37% |
| Ratio deuda/patrimonio | 85.1% |
¿Cómo se ha desempeñado CHRS a largo plazo?
Ver rendimiento histórico y comparativaAnálisis de la empresa y estado de los datos financieros
| Datos | Última actualización (huso horario UTC) |
|---|---|
| Análisis de la empresa | 2026/09/14 15:22 |
| Precio de las acciones al final del día | 2026/09/11 00:00 |
| Beneficios | 2026/06/30 |
| Ingresos anuales | 2025/12/31 |
Fuentes de datos
Los datos utilizados en nuestro análisis de empresas proceden de S&P Global Market Intelligence LLC. Los siguientes datos se utilizan en nuestro modelo de análisis para generar este informe. Los datos están normalizados, lo que puede introducir un retraso desde que la fuente está disponible.
| Paquete | Datos | Marco temporal | Ejemplo Fuente EE.UU. * |
|---|---|---|---|
| Finanzas de la empresa | 10 años |
| |
| Estimaciones del consenso de analistas | +3 años |
|
|
| Precios de mercado | 30 años |
| |
| Propiedad | 10 años |
| |
| Gestión | 10 años |
| |
| Principales avances | 10 años |
|
* Ejemplo para valores de EE.UU., para no EE.UU. se utilizan formularios y fuentes normativas equivalentes.
A menos que se especifique lo contrario, todos los datos financieros se basan en un periodo anual, pero se actualizan trimestralmente. Esto se conoce como datos de los últimos doce meses (TTM) o de los últimos doce meses (LTM). Más información.
Modelo de análisis y copo de nieve
Los detalles del modelo de análisis utilizado para generar este informe están disponibles en nuestra página de Github, también tenemos guías sobre cómo utilizar nuestros informes y tutoriales en Youtube.
Conozca al que diseñó y construyó el modelo de análisis Simply Wall St.
Métricas industriales y sectoriales
Simply Wall St calcula cada 6 horas nuestras métricas sectoriales y de sección. Los detalles de nuestro proceso están disponibles en Github.
Fuentes analistas
Coherus Oncology, Inc. está cubierta por 13 analistas. 6 de esos analistas presentaron las estimaciones de ingresos o ganancias utilizadas como datos para nuestro informe. Las estimaciones de los analistas se actualizan a lo largo del día.
| Analista | Institución |
|---|---|
| Colleen Kusy | Baird |
| Balaji Prasad | Barclays |
| Mayur Somaiya | BMO Capital Markets Equity Research |